N6-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response

Redox Biology

Volumn 2, Issue 1, 2014, Pages 580-589

  Dassano, Alice ^a   Mancuso, Mariateresa ^b   Giardullo, Paola ^c   Cecco, Loris De ^a   Ciuffreda, Pierangela ^d   Santaniello, Enzo ^e   Saran, Anna ^b   Dragani, Tommaso A ^a   Colombo, Francesca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ENEA C R CASACCIA   (Italy)

^c GUGLIELMO MARCONI UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti inflammatory drug; Gene expression; Modified nucleosides; Pathway analysis; Reactive oxygen species

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENOSINE; ANTIINFLAMMATORY AGENT; HYDROGEN PEROXIDE; LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR NRF2; 6 N BENZYLADENOSINE; ADENOSINE DERIVATIVE; N6 ALLYLADENOSINE; N6 BUTYLADENOSINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIOXIDANT; NFE2L2 PROTEIN, HUMAN; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BREAST ADENOCARCINOMA; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUCIFERASE ASSAY; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER GROWTH; CANCER INHIBITION; HL 60 CELL LINE; MCF 7 CELL LINE; NEUTROPHIL CHEMOTAXIS; OTITIS; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; OXIDATION REDUCTION REACTION; SIGNAL TRANSDUCTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; HYDROGEN PEROXIDE; ISOPENTENYLADENOSINE; MCF-7 CELLS; MICE; NF-E2-RELATED FACTOR 2; OTITIS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 84897749974     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.03.001     Document Type: Article

References (43)

1. Spinola M., Galvan A., Pignatiello C., Conti B., Pastorino U., Nicander B., Paroni R., Dragani T.A. Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer. Oncogene 2005, 24:5502-5509. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/sj.onc.1208687.
2. Golovko A., Hjälm G., Sitbon F., Nicander B. Cloning of a human tRNA isopentenyl transferase. Gene 2000, 258:85-93. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0378-1119(00)00421-2.
3. Fradejas N., Carlson B.A., Rijntjes E., Becker N.P., Tobe R., Schweizer U. Mammalian Trit1 is a tRNA([ser]sec)-isopentenyl transferase required for full selenoprotein expression. Biochemical Journal 2013, 450:427-432. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1042/BJ20121713.
4. Jenner L.B., Demeshkina N., Yusupova G., Yusupov M. Structural aspects of messenger RNA reading frame maintenance by the ribosome. Nature Structural & Molecular Biology 2010, 17:555-560. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/nsmb.1790.
5. Bifulco M., Malfitano A.M., Proto M.C., Santoro A., Caruso M.G., Laezza C. Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug. Anti-cancer Agents in Medicinal Chemistry 2008, 8:200-204. http://www.ncbi.nlm.nih.gov/pubmed/, 10.2174/187152008783497028.
6. Vold B.S., Keith D.E., Slavik M. Urine levels of N-[9-(beta-D-ribofuranosyl)purin-6-ylcarbamoyl]-l-threonine, N6-(delta 2-isopentenyl)adenosine, and 2'-O-methylguanosine as determined by radioimmunoassay for normal subjects and cancer patients. Cancer Research 1982, 42:5265-5269. http://www.ncbi.nlm.nih.gov/pubmed/.
7. Slocum H.K., Hakala M.T. Mechanism of natural resistance to N6-(delta2-isopentenyl)adenosine in cultured cells. Cancer Research 1975, 35:423-428. http://www.ncbi.nlm.nih.gov/pubmed/.
8. Jones R., Grace J.T., Mittelman A., Woodruff M.W. Human pharmacology and initial clinical trail of isopentenyl adenosine (IPA). Proceedings of the American Association for Cancer Research 1968, 9:35.
9. Suk D., Simpson C.L., Mihich E. Toxicological and antiproliferative effects of N6-(delta2-isopentenyl) adenosine, a natural component of mammalian transfer RNA. Cancer Research 1970, 30:1429-1436. http://www.ncbi.nlm.nih.gov/pubmed/.
10. Mittelman A., Evans J.T., Chheda G.B. Cytokinins as chemotherapeutic agents. Annals of the New York Academy of Sciences 1975, 255:225-234. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1749-6632.1975.tb29228.x.
11. Colombo F., Falvella F.S., De Cecco L., Tortoreto M., Pratesi G., Ciuffreda P., Ottria R., Santaniello E., Cicatiello L., Weisz A., Dragani T.A. Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine. International Journal of Cancer. Journal international Du Cancer 2009, 124:2179-2185. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1002/ijc.24168.
12. Laezza C., Notarnicola M., Caruso M.G., Messa C., Macchia M., Bertini S., Minutolo F., Portella G., Fiorentino L., Stingo S., Bifulco M. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2006, 20:412-418. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1096/fj.05-4044lsf.
13. Castiglioni S., Casati S., Ottria R., Ciuffreda P., Maier J.A. N6-isopentenyladenosine and its analogue n6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anti-cancer Agents in Medicinal Chemistry 2013, 13:672-678. http://www.ncbi.nlm.nih.gov/pubmed/, 10.2174/1871520611313040016.
14. Laezza C., Malfitano A.M., Di Matola T., Ricchi P., Bifulco M. Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells. Molecular Carcinogenesis 2010, 49:892-901. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1002/mc.20666.
15. Spinola M., Colombo F., Falvella F.S., Dragani T.A. N6-isopentenyladenosine: a potential therapeutic agent for a variety of epithelial cancers. International Journal of Cancer. Journal international Du Cancer 2007, 120:2744-2748. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1002/ijc.22601.
16. Chheda G.B., Mittelman A. N 6-(2 -isopentenyl)adenosine metabolism in man. Biochemical Pharmacology 1972, 21:27-37. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/0006-2952(72)90247-X.
17. Meisel H., Günther S., Martin D., Schlimme E. Apoptosis induced by modified ribonucleosides in human cell culture systems. FEBS Letters 1998, 433:265-268. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/S0014-5793(98)00927-2.
18. Casati S., Ottria R., Baldoli E., Lopez E., Maier J.A., Ciuffreda P. Effects of cytokinins, cytokinin ribosides and their analogs on the viability of normal and neoplastic human cells. Anticancer Research 2011, 31:3401-3406. http://www.ncbi.nlm.nih.gov/pubmed/.
19. Blad C.C., von Frijtag Drabbe Künzel J.K., de Vries H., Mulder-Krieger T., Bar-Yehuda S., Fishman P., Ijzerman A.P. Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signalling 2011, 7:453-462. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/s11302-011-9244-9.
20. Ottria R., Casati S., Baldoli E., Maier J.A., Ciuffreda P. N-alkyladenosines: synthesis and evaluation of in vitro anticancer activity. Bioorganicand Medicinal Chemistry 2010, 18:8396-8402. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.bmc.2010.09.030.
21. Teufelhofer O., Weiss R.M., Parzefall W., Schulte-Hermann R., Micksche M., Berger W., Elbling L. Promyelocytic HL60 cells express NADPH oxidase and are excellent targets in a rapid spectrophotometric microplate assay for extracellular superoxide. Toxicological Sciences: An Official Journal of the Society of Toxicology 2003, 76:376-383. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1093/toxsci/kfg234.
22. Saran A., Neveu T., Covelli V., Mouton D., Pazzaglia S., Rebessi S., Doria G., Biozzi G. Genetics of chemical carcinogenesis: analysis of bidirectional selective breeding inducing maximal resistance or maximal susceptibility to 2-stage skin tumorigenesis in the mouse. International Journal of Cancer. Journal international Du Cancer 2000, 88:424-431. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D.
23. Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals 2011, NRC, National Research Council, National Academies Press, Washington, DC.
24. Wright G.W., Simon R.M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003, 19:2448-2455. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1093/bioinformatics/btg345.
25. J.C. Oliveros, VENNY. An Interactive Tool for Comparing Lists with Venn Diagrams, 2007.
26. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B 1995, 57:289-300.
27. Galvan A., Vorraro F., Cabrera W.H., Ribeiro O.G., Pazzaglia S., Mancuso M., Zolin A., Milani S., Saran A., Ibañez O.M., Dragani T.A. Genetic heterogeneity of inflammatory response and skin tumorigenesis in phenotypically selected mouse lines. Cancer Letters 2010, 295:54-58. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.canlet.2010.02.013.
28. Fox J. The R commander:a basic-statistics graphical user interface to R. Journal of Statistical Software 2005, 19:1-42.
29. Baird L., Dinkova-Kostova A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Archives of Toxicology 2011, 85:241-272. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1007/s00204-011-0674-5.
30. Jeong W.S., Jun M., Kong A.N. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxidants & Redox Signaling 2006, 8:99-106. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1089/ars.2006.8.99.
31. Malhotra D., Thimmulappa R., Vij N., Navas-Acien A., Sussan T., Merali S., Zhang L., Kelsen S.G., Myers A., Wise R., Tuder R., Biswal S. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. American Journal of Respiratory and Critical Care Medicine 2009, 180:1196-1207. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1164/rccm.200903-0324OC.
32. Conklin K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies 2004, 3:294-300. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1177/1534735404270335.
33. Chen Y., Jungsuwadee P., Vore M., Butterfield D.A., St Clair D.K. Collateral damage in cancer chemotherapy:oxidative stress in nontargeted tissues. Molecular interventions 2007, 7:147-156. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1124/mi.7.3.6.
34. Tiligada E. Chemotherapy: induction of stress responses. Endocrine-related Cancer 2006, 13(Suppl. 1):S115-S124. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1677/erc.1.01272.
35. Lee J.H., Khor T.O., Shu L., Su Z.Y., Fuentes F., Kong A.N. Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacology & Therapeutics 2013, 137:153-171. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.pharmthera.2012.09.008.
36. Reinhardt H.C., Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends in Genetics 2012, 28:128-136. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.tig.2011.12.002.
37. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets-what are the challenges?. Nature Reviews. Drug Discovery 2013, 12:265-286. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/nrd3955.
38. van der Hoeven D., Wan T.C., Auchampach J.A. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology 2008, 74:685-696. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1124/mol.108.048066.
39. Fishman P., Bar-Yehuda S., Liang B.T., Jacobson K.A. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discovery Today 2012, 17:359-366. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.drudis.2011.10.007.
40. Kadmiel M., Cidlowski J.A. Glucocorticoid receptor signaling in health and disease. Trends in Pharmacological Sciences 2013, 34:518-530. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.tips.2013.07.003.
41. Ma Q., Battelli L., Hubbs A.F. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. American Journal of Pathology 2006, 168:1960-1974. http://www.ncbi.nlm.nih.gov/pubmed/, 10.2353/ajpath.2006.051113.
42. Lu H., Cui W., Klaassen C.D. Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. Toxicology and Applied Pharmacology 2011, 256:122-135. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.taap.2011.07.019.
43. Hirota A., Kawachi Y., Yamamoto M., Koga T., Hamada K., Otsuka F. Acceleration of UVB-induced photoageing in nrf2 gene-deficient mice. Experimental Dermatology 2011, 20:664-668. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1600-0625.2011.01292.x.